




Epidemiological week /
Semana epidemiológica:

2026-06

Respiratory Viruses weekly report Reporte semanal de Virus Respiratorios

Data as of February 20, 2026 /
Datos hasta el 20 de Febrero de 2026



Respiratory Viruses Team / Equipo de Virus Respiratorios
(Infectious Hazard Management Unit / Unidad de Gestión de Amenazas Infecciosas)



Cover/Portada	Subregional NAM
Data sources	CAN
Method.Note ENG	MEX
Method.Note ESP	MEX 2
Summary/Resumen ENG	USA
Summary/Resumen ENG 2	USA 2
Summary/Resumen ESP	Subregional CAR.
Summary/Resumen ESP 2	BLZ
Regional INF	CUB
Regional INF 4 EW/SE	DOM
Regional RSV	JAM
Regional SC-2	LCA
Regional ORV	BRB
Regional SARI-IRAG	CYM
% Positivity/%Positividad	GUY
Regional ILI- ETI	VCT
Subregional NAM	Subregional CAM.
Subregional CAR.	GTM
Subregional CAM.	HND
Subregional AND.	HND 2
Subregional BSC.	NIC
	PAN
	Subregional AND.
	BOL
	BOL 2
	COL
	COL 2
	ECU
	ECU 2
	PER
	PER 2
	Subregional BSC.
	ARG
	BRA
	BRA 2
	CHL
	CHL 2
	PRY
	PRY 2





The information presented in this update is based on data provided by Ministries of Health and National Influenza Centers of Member States to the global informatics platforms FluNet and FluID; and open data that Ministries of Health published on its website or shared with PAHO/WHO.

© Pan American Health Organization, 2024
Somerrights reserved. This work is available under license CC BY-NC-SA 3.0 IGO.

La información presentada en esta actualización se obtiene a partir de los datos notificados por los Ministerios de Salud y los Centros Nacionales de Influenza de los Estados Miembros a las plataformas informáticas globales de la OPS/OMS: FluNet y FluID; y de los datos en abierto que los Ministerios de Salud publican en sus páginas web o comparten con la OPS/OMS.

© Organización Panamericana de la Salud, 2024
Algunos derechos reservados. Esta obra está disponible en virtud de la licencia CC BY-NC-SA 3.0 IGO.

PAHO interactive data / Datos interactivos de la OPS:

PAHO Influenza: [Influenza Situation - Region of the Americas - PAHO/WHO | Pan American Health Organization](#)

PAHO RSV: [Respiratory Syncytial Virus \(RSV\) Situation - Region of the Americas - PAHO/WHO | Pan American Health Organization](#)

PAHO COVID-19: [SARS CoV2 Situation - Region of the Americas - PAHO/WHO | Pan American Health Organization](#)

Situation Report / Informe de situación: [Influenza Situation Report - PAHO/WHO | Pan American Health Organization](#)

Severe acute respiratory infections network – SARInet plus
Red de las infecciones respiratorias agudas graves – SARInet plus
<http://www.sarinet.org>





Abbreviations Glossary:

ILI: Influenza-Like Illness
ARI: Acute Respiratory Infection
SARI: Severe Acute Respiratory Infection
RSV: Respiratory Syncytial Virus
SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus 2
WHO: World Health Organization
PISA: Pandemic Influenza Severity Assessment

Percentage positivity from FluNet data:

The positivity percentages reported in FluNet are derived from the national total of processed and reported samples, encompassing both sentinel and non-sentinel origins. Countries exclusively reporting sentinel data will see this information reflected in the bulletin, while those reporting from both sources will obtain indicators resulting from a combination of both. For calculating the positivity percentage for influenza, RSV, and other respiratory viruses, the denominator includes the total processed samples (excluding SARS-CoV-2). For the SARS-CoV-2 positivity percentage, the denominator includes the total samples processed specifically for this virus, reported separately. All percentages are smoothed by applying a moving average with a 3-week window that includes data from the reference week and the previous two weeks.

Percentage of cases attributable to respiratory viruses for ILI and SARI from FluID data:

The percentages of cases attributable to influenza, RSV, and SARS-CoV-2 over the total ILI or SARI cases reflect the relative contribution of each respiratory virus to the total cases of ILI and SARI. This information is obtained by dividing the total positive cases of ILI or SARI for each respiratory virus by the total reported cases of ILI or SARI for the corresponding epidemiological week. All percentages are smoothed by applying a moving average with a 3-week window that includes data from the reference week and the previous two weeks.

PISA Graphs:

PISA graphs use data reported to FluNet (influenza positivity percentages) and FluID (cases of ILI, SARI, ARI, and pneumonia). For syndromic data reported to FluID, if the country reports weekly denominators of outpatients and hospitalizations, these are used to calculate weekly cases of ILI/1000 outpatients and weekly cases of SARI/100 hospitalizations, upon which thresholds are determined. Alternatively, if denominators are unavailable, case counts for each syndrome (ILI, SARI, ARI, or pneumonia) are used to calculate thresholds. The reflected thresholds are calculated using the WHO average curve methodology (available at: [WHO Average Curves \(shinyapps.io\)](https://shinyapps.io/WHO-Average-Curves/)) with historical data from available previous seasons (excluding seasons with atypical patterns due to epidemiological context or changes in surveillance systems, such as the years 2009 and 2010 and the years 2020 to 2023).





Regional Situation: Influenza activity in the Americas stabilized this week compared to the previous epidemiological week (EW), following a sustained downward trend, with a regional positivity of 15.6%. Influenza A(H3N2) predominated among subtyped influenza A samples in most regions, except in the Andean subregion, where A(H3N2) cocirculated with A(H1N1)pdm09. RSV circulation continued its upward trend, reaching a positivity of 1.9%, while the decreasing trend of SARS-CoV-2 slowed, reaching a positivity of 5.1%. In North America, influenza positivity continued to decline, reaching 7.4%. RSV activity increased over the past three EWs (7.4%), while SARS-CoV-2 positivity remained stable at 4.9%. In the Caribbean, influenza circulation remained elevated, with a positivity rate of around 30.5% over the past three EWs. RSV activity decreased compared to the previous EW (3.3%), and SARS-CoV-2 circulation remained stable at intraseasonal levels (<1%). In Central America, influenza activity continued to decline, reaching a positivity of 16.8%. SARS-CoV-2 remained at low and stable levels (<1%), and RSV circulation remained stable (4.8%). In the Andean subregion, influenza activity remained stable, with a positivity of 12.2%. RSV circulation increased this EW (4.3%), and SARS-CoV-2 circulation decreased compared to the previous EW (1.9%). In Brazil and the Southern Cone, influenza activity has continued to decline since mid-December, with a positivity of 3%. RSV circulation remains at interseasonal levels (<1%), while SARS-CoV-2 activity decreased compared to the previous EW (7.7%). Circulation of other respiratory viruses (ORV) increased to 1.7% regionally, with rhinovirus, coronaviruses and metapneumovirus being the most frequently detected.

North America: Influenza activity has continued to decline since late December, with a positivity rate of 7.4%. Influenza B accounted for approximately 25% of influenza samples in the past four weeks. RSV circulation continues increasing (7.4%), while SARS-CoV-2 activity remained stable (4.9%). SARI cases associated with influenza continued over 10%. In Canada and Mexico, influenza circulation is at epidemic levels, with downward trends, at positivity rates of 6.3% and 22.3%, respectively. In the United States, influenza circulation is stable, with a positivity of 18.2%, predominantly associated with influenza A(H3N2). Regarding SARS-CoV-2, positivity remained stable in Canada (5.2%) and Mexico (1.0%), and slightly decreased in the United States (5.0%). RSV activity increased in Canada (7.6%) and the United States (7.6%), while remaining stable in Mexico (4.6%).

Caribbean: Influenza activity continues around 30% over the past four EWs, with influenza A(H3N2) predominating over the past four weeks. RSV circulation decreased compared with the previous three EWs (3.3%), while SARS-CoV-2 activity continues at interseasonal levels (<1%). At the country level, influenza activity increased in the Dominican Republic (23.8%), and the Cayman Islands (43.3%). No clear trend was identified in Belize (20.3%), Jamaica (46.3%), while decreases were observed in Cuba (3.6%), Saint Lucia (35.2%), Barbados (8.3%), Guyana (18.4%), Saint Vincent and the Grenadines (12.5%). RSV positivity decreased in Belize (6.8%), Cuba (10.7%), Cayman Islands (1.7%), was stable in Jamaica (6.7%), Guyana (1.0%), while increased in Saint Lucia (5.0%). SARS-CoV-2 activity remained low and stable.

Central America: Influenza activity decreased compared to the previous EW (9.3%), with cocirculation of influenza A and B. RSV circulation remained elevated (9.9%), while SARS-CoV-2 activity remained low and stable (<1.0%).

By Country:

- **Guatemala:** Influenza activity increased compared to the previous two EWs, reaching high levels and a positivity of 39.6%. RSV circulation remained stable at 4.0%. SARS-CoV-2 remained below 1%. SARI cases continued decreasing, mainly associated with influenza.
- **Honduras:** Influenza circulation continues decreasing, reaching a positivity of 17.6% at epidemic levels. SARI cases associated with influenza continued decreasing.
- **Nicaragua:** Influenza circulation continued to decrease for four consecutive EWs, reaching a positivity of 7.1% at interseasonal levels. RSV activity decreased to 2.0%, while SARS-CoV-2 remained at interseasonal levels.
- **Panama:** Influenza activity maintained a downward trend, reaching a positivity of 13.1%. RSV circulation remained high with an upward trend, reaching a positivity of 16.4%. SARS-CoV-2 remained low.

Continues on the next page





Andean Subregion: Influenza activity slightly decreased compared to the previous EW (12.2%). RSV circulation increased over the past two EWs (4.3%), while SARS-CoV-2 activity decreased compared to the previous EW (1.9%).

By Country:

- **Bolivia:** Influenza circulation continued increasing, reaching a positivity of 47.2%, while RSV activity decreased below 1%.
- **Colombia:** Influenza activity decreased compared to the previous EW, with a current positivity of 11.1%, and influenza A(H1N1)pdm09 as the predominant subtype. RSV activity increased, with positivity of 5.4%, while SARS-CoV-2 decreased compared to the previous EW, reaching a positivity of 1.6%.
- **Ecuador:** Influenza activity continued decreasing over three EW, reaching a positivity of 15.9%. RSV circulation increased compared to the previous EW to 4.6%, and SARS-CoV-2 decreased below 1%.
- **Peru:** Influenza circulation increased compared to the previous EW, reaching a positivity of 12.5%, at epidemic levels. RSV activity also slightly increased to 1.2%, while SARS-CoV-2 remained stable at 4.4%.

Brazil and the Southern Cone: Influenza activity continued to decrease subregionally, reaching a positivity of 3.0%, predominantly associated with influenza A(H3N2). RSV circulation remained low and stable at interseasonal levels, while SARS-CoV-2 activity also decreased over the past EWs, with a positivity of 7.7%. SARI cases continued to decrease, mainly associated with influenza, followed by SARS-CoV-2.

By Country:

- **Argentina:** Influenza circulation continues to increase over two EW, reaching epidemic levels, at a positivity of 5.2%. RSV activity continues at low levels with a positivity below 1%, and SARS-CoV-2 activity decreased over the last two EWs with 4.6% positivity.
- **Brazil:** Influenza activity continues stable below epidemic levels, at a positivity of 2.7%, with circulation mainly of influenza A(H3N2). RSV is also stable at interseasonal levels, as well as SARS-CoV-2 circulation, with a positivity of 7.7%.
- **Chile:** Influenza activity decreased below epidemic levels, with a positivity of 1.9%. SARS-CoV-2 activity maintained a declining trend, reaching a 9.3% positivity, while RSV circulation remains at low and stable levels. The largest proportion of SARI cases corresponds to SARS-CoV-2.
- **Paraguay:** Influenza activity maintains a sustained decrease, reaching a positivity of 16.4%. RSV circulation remains stable, below 1%, while SARS-CoV-2 circulation decreased compared to the previous EW, with 5.4% positivity.

Global: Available at: [Global Influenza Programme \(who.int\)](https://www.who.int/programs/global-influenza-programme).

Avian Influenza: A summary of the avian influenza situation in the region, case management and recommendations are available at [Epidemiological alerts and updates | PAHO/WHO](https://www.paho.org/en/epidemiological-alerts-and-updates) | [Pan American Health Organization \(paho.org\)](https://www.paho.org).





Situación regional: La actividad de influenza en las Américas se estabilizó esta semana en comparación con la semana epidemiológica (SE) previa, tras una tendencia sostenida a la baja, con una positividad regional de 15.6%. La influenza A(H3N2) predominó entre las muestras de influenza A subtipificadas en la mayoría de las regiones, excepto en la subregión Andina, donde A(H3N2) cocirculó con A(H1N1)pdm09. La circulación de VRS continuó su tendencia ascendente, alcanzando una positividad de 1.9%, mientras que la tendencia descendente de SARS-CoV-2 se desaceleró, alcanzando una positividad de 5.1%. En América del Norte, la positividad de influenza continuó disminuyendo, alcanzando 7.4%. La actividad de VRS aumentó en las últimas tres SE (7.4%), mientras que la positividad de SARS-CoV-2 se mantuvo estable en 4.9%. En el Caribe, la circulación de influenza se mantuvo elevada, con una positividad de alrededor de 30.5% en las últimas tres SE. La actividad de VRS disminuyó en comparación con la SE previa (3.3%), y la circulación de SARS-CoV-2 se mantuvo estable en niveles interestacionales (<1%). En Centroamérica, la actividad de influenza continuó disminuyendo, alcanzando una positividad de 16.8%. SARS-CoV-2 se mantuvo en niveles bajos y estables (<1%), y la circulación de VRS permaneció estable (4.8%). En la subregión Andina, la actividad de influenza A se mantuvo estable, con una positividad de 12.2%. La circulación de VRS aumentó en esta SE (4.3%), y la circulación de SARS-CoV-2 disminuyó en comparación con la SE previa (1.9%). En Brasil y el Cono Sur, la actividad de influenza ha continuado disminuyendo desde mediados de diciembre, con una positividad de 3%. La circulación de VRS permanece en niveles interestacionales (<1%), mientras que la actividad de SARS-CoV-2 disminuyó en comparación con la SE previa (7.7%). La circulación de otros virus respiratorios (OVR) aumentó a 1.7% a nivel regional, siendo rinovirus, coronavirus y metapneumovirus los detectados con mayor frecuencia.

América del Norte: La actividad de influenza ha continuado disminuyendo desde finales de diciembre, con una positividad de 7.4%. La influenza B representó aproximadamente el 25% de las muestras de influenza en las últimas cuatro semanas. La circulación de VRS continúa en aumento (7.4%), mientras que la actividad de SARS-CoV-2 se mantuvo estable (4.9%). Los casos de IRAG asociados a influenza continuaron por encima del 10%. En Canadá y México, la circulación de influenza se encuentra en niveles epidémicos, con tendencias descendentes, con positividad de 6.3% y 22.3%, respectivamente. En Estados Unidos, la circulación de influenza se mantiene estable, con una positividad de 18.2%, predominantemente asociada a influenza A(H3N2). En relación con SARS-CoV-2, la positividad se mantuvo estable en Canadá (5.2%) y México (1.0%), y disminuyó ligeramente en Estados Unidos (5.0%). La actividad de VRS aumentó en Canadá (7.6%) y Estados Unidos (7.6%), mientras que se mantuvo estable en México (4.6%).

Caribe: La actividad de influenza continúa alrededor de 30% en las últimas cuatro SE, con predominio de influenza A(H3N2) en las últimas 4 semanas. La circulación de VRS disminuyó en comparación con las tres SE previas (3.3%), mientras que la actividad de SARS-CoV-2 continúa en niveles interestacionales (<1%). A nivel de país, la actividad de influenza aumentó en República Dominicana (23.8%) y en Islas Caimán (43.3%). No se identificó una tendencia clara en Belice (20.3%) y Jamaica (46.3%), mientras que se observaron disminuciones en Cuba (3.6%), Santa Lucía (35.2%), Barbados (8.3%), Guyana (18.4%) y San Vicente y las Granadinas (12.5%). La positividad de VRS disminuyó en Belice (6.8%), Cuba (10.7%) e Islas Caimán (1.7%), se mantuvo estable en Jamaica (6.7%) y Guyana (1.0%), mientras que aumentó en Santa Lucía (5.0%). La actividad de SARS-CoV-2 se mantuvo baja y estable.

Centroamérica: La actividad de influenza disminuyó en comparación con la SE previa (9.3%), con cocirculación de influenza A y B. La circulación de VRS se mantuvo elevada (9.9%), mientras que la actividad de SARS-CoV-2 permaneció baja y estable (<1.0%).

Por país:

- **Guatemala:** La actividad de influenza aumentó en comparación con las dos SE previas, alcanzando niveles altos y una positividad de 39.6%. La circulación de VRS se mantuvo estable en 4.0%. SARS-CoV-2 se mantuvo por debajo de 1%. Los casos de IRAG continuaron disminuyendo, principalmente asociados a influenza.

Continúa en la siguiente página





- **Honduras:** La circulación de influenza continúa disminuyendo, alcanzando una positividad de 17.6% en niveles epidémicos. Los casos de IRAG asociados a influenza continuaron disminuyendo.
- **Nicaragua:** La circulación de influenza continuó disminuyendo durante cuatro SE consecutivas, alcanzando una positividad de 7.1% en niveles interestacionales. La actividad de VRS disminuyó a 2.0%, mientras que SARS-CoV-2 permaneció en niveles interestacionales.
- **Panamá:** La actividad de influenza mantuvo una tendencia descendente, alcanzando una positividad de 13.1%. La circulación de VRS se mantuvo alta con tendencia ascendente, alcanzando una positividad de 16.4%. SARS-CoV-2 se mantuvo bajo.

Subregión Andina: La actividad de influenza disminuyó ligeramente en comparación con la SE previa (12.2%). La circulación de VRS aumentó en las últimas dos SE (4.3%), mientras que la actividad de SARS-CoV-2 disminuyó en comparación con la SE previa (1.9%).

Por país:

- **Bolivia:** La circulación de influenza continuó aumentando, alcanzando una positividad de 47.2%, mientras que la actividad de VRS disminuyó por debajo de 1%.
- **Colombia:** La actividad de influenza disminuyó en comparación con la SE previa, con una positividad actual de 11.1% y predominio del subtipo influenza A(H1N1)pdm09. La actividad de VRS aumentó, con una positividad de 5.4%, mientras que SARS-CoV-2 disminuyó en comparación con la SE previa, alcanzando una positividad de 1.6%.
- **Ecuador:** La actividad de influenza continuó disminuyendo durante tres SE, alcanzando una positividad de 15.9%. La circulación de VRS aumentó en comparación con la SE previa a 4.6%, y SARS-CoV-2 disminuyó por debajo de 1%.
- **Perú:** La circulación de influenza aumentó en comparación con la SE previa, alcanzando una positividad de 12.5%, en niveles epidémicos. La actividad de VRS también aumentó ligeramente a 1.2%, mientras que SARS-CoV-2 se mantuvo estable en 4.4%.

Brasil y el Cono Sur: La actividad de influenza continuó disminuyendo a nivel subregional, alcanzando una positividad de 3.0%, predominantemente asociada a influenza A(H3N2). La circulación de VRS se mantuvo baja y estable en niveles interestacionales, mientras que la actividad de SARS-CoV-2 también disminuyó en las últimas SE, con una positividad de 7.7%. Los casos de IRAG continuaron disminuyendo, principalmente asociados a influenza, seguidos por SARS-CoV-2.

Por país:


- **Argentina:** La circulación de influenza continúa aumentando durante dos SE, alcanzando niveles epidémicos, con una positividad de 5.2%. La actividad de VRS continúa en niveles bajos con una positividad por debajo de 1%, y la actividad de SARS-CoV-2 disminuyó en las últimas dos SE con 4.6% de positividad.
- **Brasil:** La actividad de influenza continúa estable por debajo de niveles epidémicos, con una positividad de 2.7%, con circulación principalmente de influenza A(H3N2). El VRS también se mantiene estable en niveles interestacionales, al igual que la circulación de SARS-CoV-2, con una positividad de 7.7%.
- **Chile:** La actividad de influenza disminuyó por debajo de niveles epidémicos, con una positividad de 1.9%. La actividad de SARS-CoV-2 mantuvo una tendencia descendente, alcanzando una positividad de 9.3%, mientras que la circulación de VRS permanece en niveles bajos y estables. La mayor proporción de casos de IRAG corresponde a SARS-CoV-2.
- **Paraguay:** La actividad de influenza mantiene una disminución sostenida, alcanzando una positividad de 16.4%. La circulación de VRS se mantiene estable, por debajo de 1%, mientras que la circulación de SARS-CoV-2 disminuyó en comparación con la SE previa, con una positividad de 5.4%.

Global: Disponible en: [Global Influenza Programme \(who.int\)](https://www.who.int/global-influenza-programme)


Influenza Aviar: el resumen sobre la situación epidemiológica de influenza aviar en la región, manejo de los casos y recomendaciones se encuentran disponibles en [Alertas y actualizaciones epidemiológicas | OPS/OMS | Organización Panamericana de la Salud \(paho.org\)](#)



Influenza virus distribution and percent positivity/Distribución de virus de influenza y porcentaje de positividad




Influenza virus distribution in the last 4 EWs/Distribución de virus de influenza en las últimas 4 SE
Global




● AH1N12009 ● AH3 ● A not subtyped ● B Victoria ● B Yamagata ● B not determined ● AH1


North America/Norte América




Caribbean/Caribe




Central America/
Centro América









Andean Region/
Región Andina



Brazil and Southern Cone/
Brasil y Cono Sur




RSV distribution and percent positivity/Distribución de VRS y porcentaje de positividad











SARS-CoV-2 distribution and percent positivity/Distribución de SARS-CoV-2 y porcentaje de positividad



ORV distribution and percent positivity/Distribución de OVR y porcentaje de positividad






New SARI cases total and by etiological agent per EW in the last 24 months/Nuevos casos IRAG totales y por agente etiológico por SE en los últimos 24 meses

Region of the Americas/ Región de las Américas

● Influenza (+) ● RSV (+) ● SARS-CoV-2 (+) ● Total cases/Casos totales






Data reported to FluNet/Datos notificados a través de FluNet

Influenza, RSV, and SARS-CoV-2 distribution/Distribución de los virus influenza, VRS y SARS-CoV-2

● Samples (+) influenza ● Samples (+) RSV ● Samples (+) SC-2 ● % (+) INF ● % (+) RSV ● % (+) SC-2






New ILI cases total and by etiological agent per EW in the last 24 months/Nuevos casos ETI totales y por agente etiológico por SE en los últimos 24 meses

Region of the Americas/ Región de las Américas



● Influenza (+) ● RSV (+) ● SARS-CoV-2 (+) ● Total cases/Casos totales




Data reported to FluNet/Datos notificados a través de FluNet

Influenza, RSV, and SARS-CoV-2 distribution/Distribución de los virus influenza, VRS y SARS-CoV-2


● Samples (+) influenza ● Samples (+) RSV ● Samples (+) SC-2 ● % (+) INF ● % (+) RSV ● % (+) SC-2



Influenza virus distribution/Distribución de virus de influenza




Influenza virus distribution last 4 EWs/Distribución de virus de influenza últimas 4 SE




Data reported to FluID/Datos notificados a través de FluID

No. new ILI cases by EW and % of ILI positive cases by virus/ N° de casos ETI nuevos por SE % de ETI positivos por virus





No. new SARI cases by EW and % of SARI positive cases by virus/ N° de casos IRAG nuevos por SE % de IRAG positivos por virus




Data reported to FluNet/Datos notificados a través de FluNet

Influenza, RSV, and SARS-CoV-2 distribution/Distribución de los virus influenza, VRS y SARS-CoV-2


Samples (+) influenza Samples (+) RSV Samples (+) SC-2 % (+) INF % (+) RSV % (+) SC-2



Influenza virus distribution/Distribución de virus de influenza




Influenza %+ by EW/ %+ influenza por SE




Influenza virus distribution last 4 EWs/Distribución de virus de influenza últimas 4 SE

- AH1N12009
- AH3
- A not subtyped
- B Victoria
- B Yamagata
- B not determined
- AH1




ORV distribution/Distribución de ORV




Data reported to FluNet/Datos notificados a través de FluNet


Influenza, RSV, and SARS-CoV-2 distribution/Distribución de los virus influenza, VRS y SARS-CoV-2




Influenza virus distribution/Distribución de virus de influenza




Influenza %+ by EW/ %+ influenza por SE



Influenza virus distribution last 4 EWs/Distribución de virus de influenza últimas 4 SE




ORV distribution/Distribución de ORV






Data reported to FluID/Datos notificados a través de FluID


No. new ILI cases by EW and % of SARI positive cases by virus/ N° de casos ETI nuevos por SE % de IRAG positivos por virus




No. new ILI positive cases by EW and positive virus/ N° de casos ETI positivos nuevos por SE y virus positivos




No. new SARI cases by EW and % of SARI positive cases by virus/ N° de casos IRAG nuevos por SE % de IRAG positivos por virus




No. new SARI positive cases by EW and positive virus/ N° de casos IRAG positivos nuevos por SE y virus positivos



No. new SARI positive deaths by EW and positive virus/ N° de defunciones IRAG positivas nuevas por SE y virus positivo




No. new SARI positive cases admitted to ICU by EW and positive virus/ N° de casos IRAG positivos nuevos con ingreso en UCI por SE y virus positivo




PISA thresholds/Umbrales PISA

No. new ILI cases by EW/N° de casos ETI nuevos por SE



No. new SARI cases by EW/N° de casos IRAG nuevos por SE





Data available from open sources / Datos disponibles en abierto en: data.cdc.gov

Percent of Tests Positive for Respiratory Viruses

Last 4 EWs/Últimas 4 SE


Pathogen ● COVID-19 ● Influenza ● RSV

Pathog... ● COVID-19 ● Influenza ● RSV




Data reported to FluNet / Datos notificados a través de FluNet


Influenza virus distribution / Distribución de virus de influenza




Influenza %+ by EW / %+ influenza por SE



Influenza virus distribution last 4 EWs / Distribución de virus de influenza últimas 4 SE




Influenza, RSV, and SARS-CoV-2 distribution / Distribución de los virus influenza, VRS y SARS-CoV-2






Data reported to FluID/Datos notificados a través de FluID

No. new ILI cases by EW and % of ILI positive cases by virus/ N° de casos ETI nuevos por SE % de ETI positivos por virus



Data available from open sources/Datos disponibles en abierto en: data.cdc.gov

Influenza, COVID-19 and RSV Hospitalization Rates (cases per 100 000 population)/Tasas de hospitalización para Influenza, VRS y COVID-19 (casos por 100.000 habitantes)





Open data set available at: [Rates of Laboratory-Confirmed RSV, COVID-19, and Flu Hospitalizations from the RESP-NET Surveillance Systems | Data | Centers for Disease Control and Prevention](#)




Data reported to FluNet/Datos notificados a través de FluNet

Influenza, RSV, and SARS-CoV-2 distribution/Distribución de los virus influenza, VRS y SARS-CoV-2


● Samples (+) influenza ● Samples (+) RSV ● Samples (+) SC-2 ● % (+) INF ● % (+) RSV ● % (+) SC-2



Influenza virus distribution/Distribución de virus de influenza




Influenza virus distribution last 4 EWs/Distribución de virus de influenza últimas 4 SE




Data reported to FluID/Datos notificados a través de FluID

No. new ILI cases by EW and % of ILI positive cases by virus/ N° de casos ETI nuevos por SE % de ETI positivos por virus




No. new SARI cases by EW and % of SARI positive cases by virus/ N° de casos IRAG nuevos por SE % de IRAG positivos por virus






Data reported to FluNet/Datos notificados a través de FluNet


Influenza, RSV, and SARS-CoV-2 distribution/Distribución de los virus influenza, VRS y SARS-CoV-2




Influenza virus distribution/Distribución de virus de influenza




Influenza %+ by EW/ %+ influenza por SE



Influenza virus distribution last 4 EWs/Distribución de virus de influenza últimas 4 SE




ORV distribution/Distribución de OVR




Data reported to FluNet/Datos notificados a través de FluNet


Influenza, RSV, and SARS-CoV-2 distribution/Distribución de los virus influenza, VRS y SARS-CoV-2




Influenza virus distribution/Distribución de virus de influenza




Influenza %+ by EW/ %+ influenza por SE



Influenza virus distribution last 4 EWs/Distribución de virus de influenza últimas 4 SE




ORV distribution/Distribución de ORV




Data reported to FluNet/Datos notificados a través de FluNet

Influenza, RSV, and SARS-CoV-2 distribution/Distribución de los virus influenza, VRS y SARS-CoV-2


● Samples (+) influenza ● Samples (+) RSV ● Samples (+) SC-2 ● % (+) INF ● % (+) RSV ● % (+) SC-2




Influenza virus distribution/Distribución de virus de influenza



Influenza %+ by EW/ %+ influenza por SE




Influenza virus distribution last 4 EWs/Distribución de virus de influenza últimas 4 SE



Data reported to FluID/Datos notificados a través de FluID


SARI cases by EW/casos IRAG por SE






Data reported to FluNet/Datos notificados a través de FluNet


Influenza, RSV, and SARS-CoV-2 distribution/Distribución de los virus influenza, VRS y SARS-CoV-2




Influenza virus distribution/Distribución de virus de influenza




Influenza %+ by EW/ %+ influenza por SE



Influenza virus distribution last 4 EWs/Distribución de virus de influenza últimas 4 SE




ORV distribution/Distribución de ORV






Data reported to FluNet/Datos notificados a través de FluNet


Influenza, RSV, and SARS-CoV-2 distribution/Distribución de los virus influenza, VRS y SARS-CoV-2




Influenza virus distribution/Distribución de virus de influenza



Influenza virus distribution last 4 EWs/Distribución de virus de influenza últimas 4 SE




ORV distribution/Distribución de OVR



Data reported to FluID/Datos notificados a través de FluID


SARI cases by EW/casos IRAG por SE






Data reported to FluNet/Datos notificados a través de FluNet


Influenza, RSV, and SARS-CoV-2 distribution/Distribución de los virus influenza, VRS y SARS-CoV-2




Influenza virus distribution/Distribución de virus de influenza



Influenza virus distribution last 4 EWs/Distribución de virus de influenza últimas 4 SE



ORV distribution/Distribución de OVR



EW








Data reported to FluNet/Datos notificados a través de FluNet

Influenza, RSV, and SARS-CoV-2 distribution/Distribución de los virus influenza, VRS y SARS-CoV-2

● Samples (+) influenza ● Samples (+) RSV ● Samples (+) SC-2 ● % (+) INF ● % (+) RSV ● % (+) SC-2




Influenza virus distribution/Distribución de virus de influenza




Influenza virus distribution last 4 EWs/Distribución de virus de influenza últimas 4 SE

- AH1N12009
- AH3
- A not subtyped
- B Victoria
- B Yamagata
- B not determined
- AH1



ORV distribution/Distribución de OVR








Data reported to FluNet/Datos notificados a través de FluNet

Influenza, RSV, and SARS-CoV-2 distribution/Distribución de los virus influenza, VRS y SARS-CoV-2


● Samples (+) influenza ● Samples (+) RSV ● Samples (+) SC-2 ● % (+) INF ● % (+) RSV ● % (+) SC-2.




Influenza virus distribution/Distribución de virus de influenza



Influenza virus distribution last 4 EWs/Distribución de virus de influenza últimas 4 SE



ORV distribution/Distribución de ORV







Data reported to FluNet/Datos notificados a través de FluNet

Influenza, RSV, and SARS-CoV-2 distribution/Distribución de los virus influenza, VRS y SARS-CoV-2


● Samples (+) influenza ● Samples (+) RSV ● Samples (+) SC-2 ● % (+) INF ● % (+) RSV ● % (+) SC-2




Influenza virus distribution/Distribución de virus de influenza



Influenza virus distribution last 4 EWS/Distribución de virus de influenza últimas 4 SE





ORV distribution/Distribución de ORV




Data reported to FluNet/Datos notificados a través de FluNet


Influenza, RSV, and SARS-CoV-2 distribution/Distribución de los virus influenza, VRS y SARS-CoV-2



Influenza virus distribution/Distribución de virus de influenza




Influenza virus distribution last 4 EWs/Distribución de virus de influenza últimas 4 SE




Data reported to FluID/Datos notificados a través de FluID

No. new ILI cases by EW and % of ILI positive cases by virus/ N° de casos ETI nuevos por SE % de ETI positivos por virus




No. new SARI cases by EW and % of SARI positive cases by virus/ N° de casos IRAG nuevos por SE % de IRAG positivos por virus




Data reported to FluNet/Datos notificados a través de FluNet

Influenza, RSV, and SARS-CoV-2 distribution/Distribución de los virus influenza, VRS y SARS-CoV-2


● Samples (+) influenza ● Samples (+) RSV ● Samples (+) SC-2 ● % (+) INF ● % (+) RSV ● % (+) SC-2




Influenza virus distribution/Distribución de virus de influenza




Influenza %+ by EW/ %+ influenza por SE



Influenza virus distribution last 4 EWs/Distribución de virus de influenza últimas 4 SE




ORV distribution/Distribución de ORV




Data reported to FluNet/Datos notificados a través de FluNet


Influenza, RSV, and SARS-CoV-2 distribution/Distribución de los virus influenza, VRS y SARS-CoV-2




Influenza virus distribution/Distribución de virus de influenza




Influenza %+ by EW/ %+ influenza por SE



Influenza virus distribution last 4 EWs/Distribución de virus de influenza últimas 4 SE




ORV distribution/Distribución de ORV






Data reported to FluID/Datos notificados a través de FluID


No. new ILI cases by EW and % of ILI positive cases by virus/ N° de casos ETI nuevos por SE % de ETI positivos por virus




No. new ILI positive cases by EW and positive virus/ N° de casos ETI positivos nuevos por SE y virus positivos



No. new SARI cases by EW and % of SARI positive cases by virus/ N° de casos IRAG nuevos por SE % de IRAG positivos por virus




No. new SARI positive cases by EW and positive virus/ N° de casos IRAG positivos nuevos por SE y virus positivos



No. new SARI positive deaths by EW and positive virus/ N° de defunciones IRAG positivas nuevas por SE y virus positivo




No. new SARI positive cases admitted to ICU by EW and positive virus/ N° de casos IRAG positivos nuevos con ingreso en UCI por SE y virus positivo




PISA thresholds/Umbrales PISA

ILI cases by EW/casos ETI por SE




SARI cases by EW/casos IRAG por SE




Data reported to FluNet/Datos notificados a través de FluNet


Influenza, RSV, and SARS-CoV-2 distribution/Distribución de los virus influenza, VRS y SARS-CoV-2




Influenza virus distribution/Distribución de virus de influenza




Influenza %+ by EW/ %+ influenza por SE



Influenza virus distribution last 4 EWs/Distribución de virus de influenza últimas 4 SE




ORV distribution/Distribución de ORV




Data reported to FluNet/Datos notificados a través de FluNet


Influenza, RSV, and SARS-CoV-2 distribution/Distribución de los virus influenza, VRS y SARS-CoV-2




Influenza virus distribution/Distribución de virus de influenza




Influenza %+ by EW/ %+ influenza por SE



Influenza virus distribution last 4 EWs/Distribución de virus de influenza últimas 4 SE





ORV distribution/Distribución de ORV




Data reported to FluNet/Datos notificados a través de FluNet


Influenza, RSV, and SARS-CoV-2 distribution/Distribución de los virus influenza, VRS y SARS-CoV-2



Influenza virus distribution/Distribución de virus de influenza




Influenza virus distribution last 4 EWs/Distribución de virus de influenza últimas 4 SE




Data reported to FluID/Datos notificados a través de FluID

No. new ILI cases by EW and % of ILI positive cases by virus/ N° de casos ETI nuevos por SE % de ETI positivos por virus




No. new SARI cases by EW and % of SARI positive cases by virus/ N° de casos IRAG nuevos por SE % de IRAG positivos por virus




Data reported to FluNet/Datos notificados a través de FluNet


Influenza, RSV, and SARS-CoV-2 distribution/Distribución de los virus influenza, VRS y SARS-CoV-2



Influenza virus distribution/Distribución de virus de influenza




Influenza %+ by EW/ %+ influenza por SE




Influenza virus distribution last 4 EWs/Distribución de virus de influenza últimas 4 SE

- AH1N12009
- AH3
- A not subtyped
- B Victoria
- B Yamagata
- B not determined
- AH1




ORV distribution/Distribución de ORV




Data reported to FluID/Datos notificados a través de FluID


No. new ILI cases by EW and % of ILI positive cases by virus/ N° de casos ETI nuevos por SE y % de ETI positivos por virus




No. new ILI positive cases by EW and positive virus/ N° de casos ETI positivos nuevos por SE y virus positivos




No. new SARI cases by EW and % of SARI positive cases by virus/ N° de casos IRAG nuevos por SE y % de IRAG positivos por virus




No. new SARI positive cases by EW and positive virus/ N° de casos IRAG positivos nuevos por SE y virus positivos



No. new SARI positive deaths by EW and positive virus/ N° de defunciones IRAG positivas nuevas por SE y virus positivo




No. new SARI positive cases admitted to ICU by EW and positive virus/ N° de casos IRAG positivos nuevos con ingreso en UCI por SE y virus positivo



PISA thresholds/Umbrales PISA

SARI cases by EW/casos IRAG por SE








Data reported to FluNet/Datos notificados a través de FluNet

Influenza, RSV, and SARS-CoV-2 distribution/Distribución de los virus influenza, VRS y SARS-CoV-2


● Samples (+) influenza ● Samples (+) RSV ● Samples (+) SC-2 ● % (+) INF ● % (+) RSV ● % (+) SC-2



Influenza virus distribution/Distribución de virus de influenza




Influenza %+ by EW/ %+ influenza por SE




Influenza virus distribution last 4 EWs/Distribución de virus de influenza últimas 4 SE

- AH1N12009
- AH3
- A not subtyped
- B Victoria
- B Yamagata
- B not determined
- AH1




ORV distribution/Distribución de ORV






Data reported to FluID/Datos notificados a través de FluID


No. new ILI cases by EW and % of ILI positive cases by virus/ N° de casos ETI nuevos por SE y % de ETI positivos por virus




No. new ILI positive cases by EW and positive virus/ N° de casos ETI positivos nuevos por SE y virus positivos



No. new SARI cases by EW and % of SARI positive cases by virus/ N° de casos IRAG nuevos por SE y % de IRAG positivos por virus




No. new SARI positive cases by EW and positive virus/ N° de casos IRAG positivos nuevos por SE y virus positivos



No. new SARI positive deaths by EW and positive virus/ N° de defunciones IRAG positivas nuevas por SE y virus positivo




No. new SARI positive cases admitted to ICU by EW and positive virus/ N° de casos IRAG positivos nuevos con ingreso en UCI por SE y virus positivo




PISA thresholds/Umbrales PISA

SARI cases by EW/casos IRAG por SE




ARI cases by EW/casos IRA por SE




Data reported to FluNet/Datos notificados a través de FluNet


Influenza, RSV, and SARS-CoV-2 distribution/Distribución de los virus influenza, VRS y SARS-CoV-2




Influenza virus distribution/Distribución de virus de influenza




Influenza %+ by EW/ %+ influenza por SE



Influenza virus distribution last 4 EWs/Distribución de virus de influenza últimas 4 SE



ORV distribution/Distribución de ORV




Data reported to FluID/Datos notificados a través de FluID

No. new ILI cases by EW and % of ILI positive cases by virus/ N° de casos ETI nuevos por SE % de ETI positivos por virus

casos/casos


No. new SARI cases by EW and % of SARI positive cases by virus/ N° de casos IRAG nuevos por SE % de IRAG positivos por virus




No. new ILI positive cases by EW and positive virus/ N° de casos ETI positivos nuevos por SE y virus positivos

casos/casos


No. new SARI positive cases by EW and positive virus/ N° de casos IRAG positivos nuevos por SE y virus positivos



No. new SARI positive deaths by EW and positive virus/ N° de defunciones IRAG positivas nuevas por SE y virus positivo




No. new SARI positive cases admitted to ICU by EW and positive virus/ N° de casos IRAG positivos nuevos con ingreso en UCI por SE y virus positivo




PISA thresholds/Umbrales PISA

SARI cases by EW/casos IRAG por SE





Pneumonia cases by EW/casos neumonía por SE




Data reported to FluNet/Datos notificados a través de FluNet


Influenza, RSV, and SARS-CoV-2 distribution/Distribución de los virus influenza, VRS y SARS-CoV-2




Influenza virus distribution/Distribución de virus de influenza




Percent positivity for influenza by week



Influenza virus distribution last 4 EWs/Distribución de virus de influenza últimas 4 SE




ORV distribution/Distribución de ORV




Data reported to FluID/Datos notificados a través de FluID


No. new ILI cases by EW and % of ILI positive cases by virus/ N° de casos ETI nuevos por SE % de ETI positivos por virus




No. new ILI positive cases by EW and positive virus/ N° de casos ETI positivos nuevos por SE y virus positivos




No. new SARI cases by EW and % of SARI positive cases by virus/ N° de casos IRAG nuevos por SE % de IRAG positivos por virus




No. new SARI positive cases by EW and positive virus/ N° de casos IRAG positivos nuevos por SE y virus positivos



No. new SARI positive deaths by EW and positive virus/ N° de defunciones IRAG positivas nuevas por SE y virus positivo




No. new SARI positive cases admitted to ICU by EW and positive virus/ N° de casos IRAG positivos nuevos con ingreso en UCI por SE y virus positivo





PISA thresholds/Umbrales PISA

SARI cases by EW/casos IRAG por SE




Data reported to FluNet/Datos notificados a través de FluNet


Influenza, RSV, and SARS-CoV-2 distribution/Distribución de los virus influenza, VRS y SARS-CoV-2



Influenza virus distribution/Distribución de virus de influenza




Influenza virus distribution last 4 EWs/Distribución de virus de influenza últimas 4 SE




Data reported to FluID/Datos notificados a través de FluID

No. new ILI cases by EW and % of ILI positive cases by virus/ N° de casos ETI nuevos por SE % de ETI positivos por virus




No. new SARI cases by EW and % of SARI positive cases by virus/ N° de casos IRAG nuevos por SE % de IRAG positivos por virus




Data reported to FluNet/Datos notificados a través de FluNet


Influenza, RSV, and SARS-CoV-2 distribution/Distribución de los virus influenza, VRS y SARS-CoV-2




Influenza virus distribution/Distribución de virus de influenza




Influenza %+ by EW/ %+ influenza por SE



Influenza virus distribution last 4 EWs/Distribución de virus de influenza últimas 4 SE





ORV distribution/Distribución de ORV






Data reported to FluNet/Datos notificados a través de FluNet


Influenza, RSV, and SARS-CoV-2 distribution/Distribución de los virus influenza, VRS y SARS-CoV-2




Influenza virus distribution/Distribución de virus de influenza




Influenza %+ by EW/ %+ influenza por SE



Influenza virus distribution last 4 EWs/Distribución de virus de influenza últimas 4 SE




ORV distribution/Distribución de ORV






Data reported to FluID/Datos notificados a través de FluID


No. new ILI cases by EW and % of ILI positive cases by virus/ N° de casos ETI nuevos por SE y % de ETI positivos por virus




No. new ILI positive cases by EW and positive virus/ N° de casos ETI positivos nuevos por SE y virus positivos




No. new SARI cases by EW and % of SARI positive cases by virus/ N° de casos IRAG nuevos por SE y % de IRAG positivos por virus




No. new SARI positive cases by EW and positive virus/ N° de casos IRAG positivos nuevos por SE y virus positivos



No. new SARI positive deaths by EW and positive virus/ N° de defunciones IRAG positivas nuevas por SE y virus positivo




No. new SARI positive cases admitted to ICU by EW and positive virus/ N° de casos IRAG positivos nuevos con ingreso en UCI por SE y virus positivo



PISA thresholds/Umbrales PISA


SARI cases per EW/casos IRAG por SE






Data reported to FluNet/Datos notificados a través de FluNet


Influenza, RSV, and SARS-CoV-2 distribution/Distribución de los virus influenza, VRS y SARS-CoV-2




Influenza virus distribution/Distribución de virus de influenza




Influenza %+ by EW/ %+ influenza por SE



Influenza virus distribution last 4 EWs/Distribución de virus de influenza últimas 4 SE




ORV distribution/Distribución de ORV






Data reported to FluID/Datos notificados a través de FluID


No. new ILI cases by EW and % of ILI positive cases by virus/ N° de casos ETI nuevos por SE % de ETI positivos por virus




No. new ILI positive cases by EW and positive virus/ N° de casos ETI positivos nuevos por SE y virus positivos




No. new SARI cases by EW and % of SARI positive cases by virus/ N° de casos IRAG nuevos por SE % de IRAG positivos por virus




No. new SARI positive cases by EW and positive virus/ N° de casos IRAG positivos nuevos por SE y virus positivos



No. new SARI positive deaths by EW and positive virus/ N° de defunciones IRAG positivas nuevas por SE y virus positivo




No. new SARI positive cases admitted to ICU by EW and positive virus/ N° de casos IRAG positivos nuevos con ingreso en UCI por SE y virus positivo




PISA thresholds/Umbrales PISA

ILI cases by EW/casos ETI por SE



SARI cases/ 100 inpatients by EW/casos IRAG/ 100 hospitalizaciones por SE



● Average Curve ● Epidemic ● Moderate ● High ● Extraordinary ● Cases ● Average C... ● Epidemic ● Moderate ● High ● Extraordin... ● SARI-INP








Data reported to FluNet/Datos notificados a través de FluNet

Influenza, RSV, and SARS-CoV-2 distribution/Distribución de los virus influenza, VRS y SARS-CoV-2


● Samples (+) influenza ● Samples (+) RSV ● Samples (+) SC-2 ● % (+) INF ● % (+) RSV ● % (+) SC-2



Influenza virus distribution/Distribución de virus de influenza




Influenza %+ by EW/ %+ influenza por SE




Influenza virus distribution last 4 EWs/Distribución de virus de influenza últimas 4 SE

- AH1N12009
- AH3
- A not subtyped
- B Victoria
- B Yamagata
- B not determined
- AH1




ORV distribution/Distribución de ORV






Data reported to FluID/Datos notificados a través de FluID


No. new ILI cases by EW and % of ILI positive cases by virus/ N° de casos ETI nuevos por SE y % de ETI positivos por virus




No. new ILI positive cases by EW and positive virus/ N° de casos ETI positivos nuevos por SE y virus positivos




No. new SARI cases by EW and % of SARI positive cases by virus/ N° de casos IRAG nuevos por SE y % de IRAG positivos por virus




No. new SARI positive cases by EW and positive virus/ N° de casos IRAG positivos nuevos por SE y virus positivos



No. new SARI positive deaths by EW and positive virus/ N° de defunciones IRAG positivas nuevas por SE y virus positivo




No. new SARI positive cases admitted to ICU by EW and positive virus/ N° de casos IRAG positivos nuevos con ingreso en UCI por SE y virus positivo



PISA thresholds/Umbrales PISA

ILI cases / 1000 outpatients by EW/casos ETI / 1000 consultas por SE



SARI cases/ 100 inpatients by EW/casos IRAG/ 100 hospitalizaciones por SE

